Showing results (21-30 of 226) with videos related to
Sort By:
Pageof 23
European Journal of Clinical Pharmacology|July 10, 2007
Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretationMarjo J Karjalainen, Pertti J Neuvonen, Janne T BackmanBasic & Clinical Pharmacology & Toxicology|June 30, 2018
In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug InteractionsAnne M Filppula, Tiffany M Mustonen, Janne T BackmanEuropean Journal of Clinical Pharmacology|June 8, 2006
Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeineJanne T Backman, Marika T Granfors, Pertti J NeuvonenEuropean Journal of Clinical Pharmacology|October 24, 2007
Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidineJanne T Backman, Marika T Schröder, Pertti J NeuvonenBiochimica Et Biophysica Acta|July 30, 1990
Two novel c-abl mRNAs are expressed in rat parotid salivary glands during in vivo beta-adrenergic receptor stimulationP M Mertz, T Backman, A Bernards, et al.International Journal of Clinical Pharmacology and Therapeutics|June 1, 1995
Azithromycin does not increase plasma concentrations of oral midazolamJ T Backman, K T Olkkola, P J NeuvonenClinical Pharmacology and Therapeutics|January 1, 1996
Rifampin drastically reduces plasma concentrations and effects of oral midazolamJ T Backman, K T Olkkola, P J NeuvonenBasic & Clinical Pharmacology & Toxicology|September 26, 2008
In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactionsMarjo J Karjalainen, Pertti J Neuvonen, Janne T BackmanBasic & Clinical Pharmacology & Toxicology|December 21, 2005
Effect of itraconazole on the pharmacokinetics of atenololJari J Lilja, Janne T Backman, Pertti J NeuvonenEuropean Journal of Clinical Pharmacology|January 17, 2008
Celecoxib is a CYP1A2 inhibitor in vitro but not in vivoMarjo J Karjalainen, Pertti J Neuvonen, Janne T BackmanPageof 23